Results-The follow up period was from one to 18 years (mean 4*6 (SD 4.5) years). Eleven patients developed one or several recurrences of articular manifestations consisting of mild oligoarthritis (n = 8), definite spondyloarthropathy (n = 2), and rheumatoid arthritis (n = 1). The delay of the first recurrence was 18 months to 12 years after the first attack. Thirteen patients had no recurrence, but three of them developed remarkable features: rheumatoid factor, antinuclear antibodies (1/2000), Sjogren's syndrome. HLA B typing was performed in nine patients and revealed B7 (n = 2), B27 (n = 2) and B22 (n = 2). Isolated HLA B27 typing was performed in two other patients and was positive in one. Conclusion-The long term outcome of RS3PE can lead to different rheumatic diseases. RS3PE appears to be a syndrome related to the elderly onset of the rheumatic diseases, including spondyloarthropathy and rheumatoid arthritis, rather than a specific entity. Laboratory changes included a high sedimentation rate, but neither rheumatoid factor nor antinuclear antibodies (ANA). The disease was reported to be associated with the presence of HLA B7.' There was no evidence of articular erosions on radiographs. The prognosis was good; remission occurred usually within 18 months. However, stiffness of the fingers persisted sometimes.' The aim of this study was to assess the outcome of patients who presented with RS3PE in our department over the past two decades. The sudden onset and good prognosis of RS3PE have been emphasised. However, good prognosis seems to be a usual feature in elderly onset rheumatoid arthritis also.'2 A subgroup of rheumatoid arthritis in the elderly was characterised by a sudden onset, a high incidence in men, and a total remission occurring within 12 to 18 months. 13 Another peculiarity of the first patients with RS3PE described by McCarty et al, was the high incidence of the HLA B7 subtype (six of eight patients). A second paper from the same department, reporting 13 additional cases, again noted this frequency of HLA B7 haplotype (seven out of 13).'4 However, none of the four cases of RS3 PE reported by Chaouat and Le Parc was B7 positive,3 and of our nine patients in whom HLA B was studied, only two were B7 positive. Collation of all these data (n = 32) reveals the presence of the following types: B7 (n = 15), B27 (n = 7), B22 (n=2), B35 (n=4), and DR7 (n=4). The relationship of all these HLA subtypes with the spondyloarthropathies has been discussed. HLA B7, B22, and B27 belong to the B7 cross reactive group,'5 the possible relationship of HLA B35 with the spondyloarthropathies has been reported,'5 and the DR7 subtype is clearly related to peripheral spondyloarthropathy. '6 17 Thus the prevalence of these different HIA subtypes may be considered as an argument for a spondyloarthropathy.
As all peripheral spondyloarthropathies are less related to the presence of HLA B27 than ankylosing spondylitis, it is feasible that peripheral spondyloarthropathy in the elderly is not highly related to HLA B27. LOPS, as described by Dubost et al,4 is closely related to the presence of HLA B27. However, to define this new syndrome, the authors have selected a group of patients in whom many elements of spondyloarthropathy are combined: 10 of 10 were HLA B27 positive, five had sacroiliitis, and nine fulfilled Amor's criteria for spondyloarthropathy.2 Probably, many other patients have an LOPS, but do not express these characteristic features. Some patients with RS3PE may belong to this group. The similarities between RS3PE and LOPS have been emphasised elsewhere. '8 In summary, there undoubtedly exists a condition characterised by a remitting, nonrelapsing symmetrical synovitis with pitting oedema. This may be considered as 'true' RS3PE. However, quite similar initial clinical features may precede spondyloarthropathy or, to a lesser extent, rheumatoid arthritis, undifferentiated connective tissue disease, or vasculitis. '9 In this respect, RS3PE should be considered as a syndrome rather than a disease.
It appears to be related to late onset of the rheumatic diseases. As the underlying disease sometimes requires several years to manifest, long term follow up is indicated in patients with RS3PE. 
